nodes	percent_of_prediction	percent_of_DWPC	metapath
Thiabendazole—CYP1A1—Progesterone—uterine cancer	0.488	0.607	CbGbCtD
Thiabendazole—CYP1A2—Progesterone—uterine cancer	0.218	0.271	CbGbCtD
Thiabendazole—CYP1A2—Etoposide—uterine cancer	0.0976	0.121	CbGbCtD
Thiabendazole—Cholestasis—Progesterone—uterine cancer	0.00572	0.0291	CcSEcCtD
Thiabendazole—Hepatocellular injury—Progesterone—uterine cancer	0.00435	0.0221	CcSEcCtD
Thiabendazole—Hepatocellular injury—Medroxyprogesterone Acetate—uterine cancer	0.00394	0.0201	CcSEcCtD
Thiabendazole—Lymphadenopathy—Progesterone—uterine cancer	0.0037	0.0188	CcSEcCtD
Thiabendazole—Hepatic failure—Progesterone—uterine cancer	0.00351	0.0179	CcSEcCtD
Thiabendazole—Hepatic failure—Medroxyprogesterone Acetate—uterine cancer	0.00318	0.0162	CcSEcCtD
Thiabendazole—Numbness—Etoposide—uterine cancer	0.00268	0.0137	CcSEcCtD
Thiabendazole—Sensory loss—Etoposide—uterine cancer	0.00257	0.0131	CcSEcCtD
Thiabendazole—Hepatic failure—Dactinomycin—uterine cancer	0.00248	0.0126	CcSEcCtD
Thiabendazole—Hyperglycaemia—Progesterone—uterine cancer	0.00246	0.0125	CcSEcCtD
Thiabendazole—Drowsiness—Progesterone—uterine cancer	0.00243	0.0124	CcSEcCtD
Thiabendazole—Jaundice—Progesterone—uterine cancer	0.00237	0.0121	CcSEcCtD
Thiabendazole—Hyperglycaemia—Medroxyprogesterone Acetate—uterine cancer	0.00223	0.0114	CcSEcCtD
Thiabendazole—Drowsiness—Medroxyprogesterone Acetate—uterine cancer	0.0022	0.0112	CcSEcCtD
Thiabendazole—Jaundice—Medroxyprogesterone Acetate—uterine cancer	0.00215	0.0109	CcSEcCtD
Thiabendazole—Visual impairment—Progesterone—uterine cancer	0.0021	0.0107	CcSEcCtD
Thiabendazole—Erythema multiforme—Progesterone—uterine cancer	0.00206	0.0105	CcSEcCtD
Thiabendazole—Tinnitus—Progesterone—uterine cancer	0.00203	0.0104	CcSEcCtD
Thiabendazole—Visual impairment—Medroxyprogesterone Acetate—uterine cancer	0.00191	0.00971	CcSEcCtD
Thiabendazole—Erythema multiforme—Medroxyprogesterone Acetate—uterine cancer	0.00187	0.00952	CcSEcCtD
Thiabendazole—Tinnitus—Medroxyprogesterone Acetate—uterine cancer	0.00184	0.00939	CcSEcCtD
Thiabendazole—Vision blurred—Progesterone—uterine cancer	0.00179	0.00912	CcSEcCtD
Thiabendazole—Chills—Medroxyprogesterone Acetate—uterine cancer	0.00177	0.00904	CcSEcCtD
Thiabendazole—Angioedema—Progesterone—uterine cancer	0.00174	0.00884	CcSEcCtD
Thiabendazole—Stevens-Johnson syndrome—Dactinomycin—uterine cancer	0.0017	0.00868	CcSEcCtD
Thiabendazole—Convulsion—Progesterone—uterine cancer	0.00165	0.00838	CcSEcCtD
Thiabendazole—Angioedema—Medroxyprogesterone Acetate—uterine cancer	0.00157	0.00801	CcSEcCtD
Thiabendazole—Confusional state—Progesterone—uterine cancer	0.00156	0.00796	CcSEcCtD
Thiabendazole—Anaphylactic shock—Progesterone—uterine cancer	0.00155	0.0079	CcSEcCtD
Thiabendazole—Convulsion—Medroxyprogesterone Acetate—uterine cancer	0.00149	0.0076	CcSEcCtD
Thiabendazole—Liver injury—Epirubicin—uterine cancer	0.00148	0.00754	CcSEcCtD
Thiabendazole—Anorexia—Progesterone—uterine cancer	0.00148	0.00753	CcSEcCtD
Thiabendazole—Erythema multiforme—Dactinomycin—uterine cancer	0.00146	0.00743	CcSEcCtD
Thiabendazole—Hypotension—Progesterone—uterine cancer	0.00145	0.00738	CcSEcCtD
Thiabendazole—Flushing—Dactinomycin—uterine cancer	0.00143	0.00729	CcSEcCtD
Thiabendazole—Confusional state—Medroxyprogesterone Acetate—uterine cancer	0.00142	0.00722	CcSEcCtD
Thiabendazole—Anaphylactic shock—Medroxyprogesterone Acetate—uterine cancer	0.00141	0.00716	CcSEcCtD
Thiabendazole—Chills—Dactinomycin—uterine cancer	0.00138	0.00705	CcSEcCtD
Thiabendazole—Somnolence—Progesterone—uterine cancer	0.00138	0.00702	CcSEcCtD
Thiabendazole—Liver injury—Doxorubicin—uterine cancer	0.00137	0.00698	CcSEcCtD
Thiabendazole—Dyspepsia—Progesterone—uterine cancer	0.00136	0.00695	CcSEcCtD
Thiabendazole—Decreased appetite—Progesterone—uterine cancer	0.00135	0.00687	CcSEcCtD
Thiabendazole—Anorexia—Medroxyprogesterone Acetate—uterine cancer	0.00134	0.00682	CcSEcCtD
Thiabendazole—Fatigue—Progesterone—uterine cancer	0.00134	0.00681	CcSEcCtD
Thiabendazole—Hypotension—Medroxyprogesterone Acetate—uterine cancer	0.00131	0.00669	CcSEcCtD
Thiabendazole—Feeling abnormal—Progesterone—uterine cancer	0.00128	0.00651	CcSEcCtD
Thiabendazole—Coordination abnormal—Epirubicin—uterine cancer	0.00127	0.00646	CcSEcCtD
Thiabendazole—Gastrointestinal pain—Progesterone—uterine cancer	0.00127	0.00646	CcSEcCtD
Thiabendazole—Somnolence—Medroxyprogesterone Acetate—uterine cancer	0.00125	0.00636	CcSEcCtD
Thiabendazole—Hepatocellular injury—Epirubicin—uterine cancer	0.00125	0.00635	CcSEcCtD
Thiabendazole—Dyspepsia—Medroxyprogesterone Acetate—uterine cancer	0.00124	0.0063	CcSEcCtD
Thiabendazole—Stevens-Johnson syndrome—Etoposide—uterine cancer	0.00123	0.00628	CcSEcCtD
Thiabendazole—Abdominal pain—Progesterone—uterine cancer	0.00123	0.00624	CcSEcCtD
Thiabendazole—Decreased appetite—Medroxyprogesterone Acetate—uterine cancer	0.00122	0.00622	CcSEcCtD
Thiabendazole—Jaundice—Etoposide—uterine cancer	0.00121	0.00617	CcSEcCtD
Thiabendazole—Fatigue—Medroxyprogesterone Acetate—uterine cancer	0.00121	0.00617	CcSEcCtD
Thiabendazole—Leukopenia—Dactinomycin—uterine cancer	0.0012	0.00612	CcSEcCtD
Thiabendazole—Coordination abnormal—Doxorubicin—uterine cancer	0.00117	0.00598	CcSEcCtD
Thiabendazole—Feeling abnormal—Medroxyprogesterone Acetate—uterine cancer	0.00116	0.0059	CcSEcCtD
Thiabendazole—Hepatocellular injury—Doxorubicin—uterine cancer	0.00115	0.00587	CcSEcCtD
Thiabendazole—Gastrointestinal pain—Medroxyprogesterone Acetate—uterine cancer	0.00115	0.00585	CcSEcCtD
Thiabendazole—Hypersensitivity—Progesterone—uterine cancer	0.00114	0.00582	CcSEcCtD
Thiabendazole—Asthenia—Progesterone—uterine cancer	0.00111	0.00567	CcSEcCtD
Thiabendazole—Hypoaesthesia—Etoposide—uterine cancer	0.00111	0.00566	CcSEcCtD
Thiabendazole—Abdominal pain—Medroxyprogesterone Acetate—uterine cancer	0.00111	0.00566	CcSEcCtD
Thiabendazole—Pruritus—Progesterone—uterine cancer	0.0011	0.00559	CcSEcCtD
Thiabendazole—Diarrhoea—Progesterone—uterine cancer	0.00106	0.0054	CcSEcCtD
Thiabendazole—Lymphadenopathy—Epirubicin—uterine cancer	0.00106	0.0054	CcSEcCtD
Thiabendazole—Erythema multiforme—Etoposide—uterine cancer	0.00106	0.00538	CcSEcCtD
Thiabendazole—Anorexia—Dactinomycin—uterine cancer	0.00104	0.00532	CcSEcCtD
Thiabendazole—Flushing—Etoposide—uterine cancer	0.00104	0.00528	CcSEcCtD
Thiabendazole—Hypersensitivity—Medroxyprogesterone Acetate—uterine cancer	0.00104	0.00527	CcSEcCtD
Thiabendazole—Dizziness—Progesterone—uterine cancer	0.00103	0.00522	CcSEcCtD
Thiabendazole—Asthenia—Medroxyprogesterone Acetate—uterine cancer	0.00101	0.00513	CcSEcCtD
Thiabendazole—Hepatic failure—Epirubicin—uterine cancer	0.00101	0.00513	CcSEcCtD
Thiabendazole—Chills—Etoposide—uterine cancer	0.001	0.0051	CcSEcCtD
Thiabendazole—Pruritus—Medroxyprogesterone Acetate—uterine cancer	0.000994	0.00506	CcSEcCtD
Thiabendazole—Vomiting—Progesterone—uterine cancer	0.000986	0.00502	CcSEcCtD
Thiabendazole—Lymphadenopathy—Doxorubicin—uterine cancer	0.000981	0.005	CcSEcCtD
Thiabendazole—Rash—Progesterone—uterine cancer	0.000978	0.00498	CcSEcCtD
Thiabendazole—Dermatitis—Progesterone—uterine cancer	0.000977	0.00497	CcSEcCtD
Thiabendazole—Headache—Progesterone—uterine cancer	0.000971	0.00495	CcSEcCtD
Thiabendazole—Diarrhoea—Medroxyprogesterone Acetate—uterine cancer	0.000961	0.0049	CcSEcCtD
Thiabendazole—Decreased appetite—Dactinomycin—uterine cancer	0.000953	0.00485	CcSEcCtD
Thiabendazole—Fatigue—Dactinomycin—uterine cancer	0.000945	0.00481	CcSEcCtD
Thiabendazole—Hepatic failure—Doxorubicin—uterine cancer	0.000931	0.00474	CcSEcCtD
Thiabendazole—Dizziness—Medroxyprogesterone Acetate—uterine cancer	0.000929	0.00473	CcSEcCtD
Thiabendazole—Nausea—Progesterone—uterine cancer	0.000921	0.00469	CcSEcCtD
Thiabendazole—Feeling abnormal—Dactinomycin—uterine cancer	0.000903	0.0046	CcSEcCtD
Thiabendazole—Gastrointestinal pain—Dactinomycin—uterine cancer	0.000896	0.00456	CcSEcCtD
Thiabendazole—Vomiting—Medroxyprogesterone Acetate—uterine cancer	0.000893	0.00455	CcSEcCtD
Thiabendazole—Rash—Medroxyprogesterone Acetate—uterine cancer	0.000886	0.00451	CcSEcCtD
Thiabendazole—Dermatitis—Medroxyprogesterone Acetate—uterine cancer	0.000885	0.00451	CcSEcCtD
Thiabendazole—Headache—Medroxyprogesterone Acetate—uterine cancer	0.00088	0.00448	CcSEcCtD
Thiabendazole—Leukopenia—Etoposide—uterine cancer	0.00087	0.00443	CcSEcCtD
Thiabendazole—Abdominal pain—Dactinomycin—uterine cancer	0.000866	0.00441	CcSEcCtD
Thiabendazole—Convulsion—Etoposide—uterine cancer	0.000842	0.00429	CcSEcCtD
Thiabendazole—Nausea—Medroxyprogesterone Acetate—uterine cancer	0.000835	0.00425	CcSEcCtD
Thiabendazole—Hypersensitivity—Dactinomycin—uterine cancer	0.000807	0.00411	CcSEcCtD
Thiabendazole—Confusional state—Etoposide—uterine cancer	0.0008	0.00407	CcSEcCtD
Thiabendazole—Anaphylactic shock—Etoposide—uterine cancer	0.000793	0.00404	CcSEcCtD
Thiabendazole—Asthenia—Dactinomycin—uterine cancer	0.000786	0.004	CcSEcCtD
Thiabendazole—Anorexia—Etoposide—uterine cancer	0.000756	0.00385	CcSEcCtD
Thiabendazole—Diarrhoea—Dactinomycin—uterine cancer	0.00075	0.00382	CcSEcCtD
Thiabendazole—Hypotension—Etoposide—uterine cancer	0.000741	0.00377	CcSEcCtD
Thiabendazole—Hyperglycaemia—Epirubicin—uterine cancer	0.000705	0.00359	CcSEcCtD
Thiabendazole—Somnolence—Etoposide—uterine cancer	0.000705	0.00359	CcSEcCtD
Thiabendazole—Drowsiness—Epirubicin—uterine cancer	0.000697	0.00355	CcSEcCtD
Thiabendazole—Vomiting—Dactinomycin—uterine cancer	0.000697	0.00355	CcSEcCtD
Thiabendazole—Stevens-Johnson syndrome—Epirubicin—uterine cancer	0.000691	0.00352	CcSEcCtD
Thiabendazole—Rash—Dactinomycin—uterine cancer	0.000691	0.00352	CcSEcCtD
Thiabendazole—Decreased appetite—Etoposide—uterine cancer	0.00069	0.00351	CcSEcCtD
Thiabendazole—Fatigue—Etoposide—uterine cancer	0.000684	0.00348	CcSEcCtD
Thiabendazole—Jaundice—Epirubicin—uterine cancer	0.00068	0.00346	CcSEcCtD
Thiabendazole—Haematuria—Epirubicin—uterine cancer	0.000665	0.00339	CcSEcCtD
Thiabendazole—Feeling abnormal—Etoposide—uterine cancer	0.000654	0.00333	CcSEcCtD
Thiabendazole—Hyperglycaemia—Doxorubicin—uterine cancer	0.000653	0.00332	CcSEcCtD
Thiabendazole—Nausea—Dactinomycin—uterine cancer	0.000651	0.00332	CcSEcCtD
Thiabendazole—Gastrointestinal pain—Etoposide—uterine cancer	0.000649	0.0033	CcSEcCtD
Thiabendazole—Drowsiness—Doxorubicin—uterine cancer	0.000645	0.00329	CcSEcCtD
Thiabendazole—Stevens-Johnson syndrome—Doxorubicin—uterine cancer	0.00064	0.00326	CcSEcCtD
Thiabendazole—Jaundice—Doxorubicin—uterine cancer	0.000629	0.0032	CcSEcCtD
Thiabendazole—Abdominal pain—Etoposide—uterine cancer	0.000627	0.00319	CcSEcCtD
Thiabendazole—Hypoaesthesia—Epirubicin—uterine cancer	0.000623	0.00317	CcSEcCtD
Thiabendazole—Haematuria—Doxorubicin—uterine cancer	0.000615	0.00313	CcSEcCtD
Thiabendazole—Visual impairment—Epirubicin—uterine cancer	0.000603	0.00307	CcSEcCtD
Thiabendazole—Erythema multiforme—Epirubicin—uterine cancer	0.000592	0.00301	CcSEcCtD
Thiabendazole—Hypersensitivity—Etoposide—uterine cancer	0.000584	0.00298	CcSEcCtD
Thiabendazole—Tinnitus—Epirubicin—uterine cancer	0.000583	0.00297	CcSEcCtD
Thiabendazole—Flushing—Epirubicin—uterine cancer	0.000581	0.00296	CcSEcCtD
Thiabendazole—Hypoaesthesia—Doxorubicin—uterine cancer	0.000576	0.00293	CcSEcCtD
Thiabendazole—Asthenia—Etoposide—uterine cancer	0.000569	0.0029	CcSEcCtD
Thiabendazole—Chills—Epirubicin—uterine cancer	0.000562	0.00286	CcSEcCtD
Thiabendazole—Pruritus—Etoposide—uterine cancer	0.000561	0.00286	CcSEcCtD
Thiabendazole—Visual impairment—Doxorubicin—uterine cancer	0.000558	0.00284	CcSEcCtD
Thiabendazole—Erythema multiforme—Doxorubicin—uterine cancer	0.000548	0.00279	CcSEcCtD
Thiabendazole—Diarrhoea—Etoposide—uterine cancer	0.000543	0.00276	CcSEcCtD
Thiabendazole—Tinnitus—Doxorubicin—uterine cancer	0.00054	0.00275	CcSEcCtD
Thiabendazole—Flushing—Doxorubicin—uterine cancer	0.000537	0.00274	CcSEcCtD
Thiabendazole—Dizziness—Etoposide—uterine cancer	0.000525	0.00267	CcSEcCtD
Thiabendazole—Chills—Doxorubicin—uterine cancer	0.00052	0.00265	CcSEcCtD
Thiabendazole—Vision blurred—Epirubicin—uterine cancer	0.000513	0.00262	CcSEcCtD
Thiabendazole—Vomiting—Etoposide—uterine cancer	0.000504	0.00257	CcSEcCtD
Thiabendazole—Rash—Etoposide—uterine cancer	0.0005	0.00255	CcSEcCtD
Thiabendazole—Dermatitis—Etoposide—uterine cancer	0.0005	0.00254	CcSEcCtD
Thiabendazole—Headache—Etoposide—uterine cancer	0.000497	0.00253	CcSEcCtD
Thiabendazole—Leukopenia—Epirubicin—uterine cancer	0.000488	0.00248	CcSEcCtD
Thiabendazole—Vision blurred—Doxorubicin—uterine cancer	0.000475	0.00242	CcSEcCtD
Thiabendazole—Convulsion—Epirubicin—uterine cancer	0.000472	0.0024	CcSEcCtD
Thiabendazole—Nausea—Etoposide—uterine cancer	0.000471	0.0024	CcSEcCtD
Thiabendazole—Leukopenia—Doxorubicin—uterine cancer	0.000451	0.0023	CcSEcCtD
Thiabendazole—Confusional state—Epirubicin—uterine cancer	0.000448	0.00228	CcSEcCtD
Thiabendazole—Anaphylactic shock—Epirubicin—uterine cancer	0.000445	0.00226	CcSEcCtD
Thiabendazole—Convulsion—Doxorubicin—uterine cancer	0.000437	0.00222	CcSEcCtD
Thiabendazole—Anorexia—Epirubicin—uterine cancer	0.000424	0.00216	CcSEcCtD
Thiabendazole—Hypotension—Epirubicin—uterine cancer	0.000415	0.00212	CcSEcCtD
Thiabendazole—Confusional state—Doxorubicin—uterine cancer	0.000415	0.00211	CcSEcCtD
Thiabendazole—Anaphylactic shock—Doxorubicin—uterine cancer	0.000411	0.0021	CcSEcCtD
Thiabendazole—Somnolence—Epirubicin—uterine cancer	0.000395	0.00201	CcSEcCtD
Thiabendazole—Anorexia—Doxorubicin—uterine cancer	0.000392	0.002	CcSEcCtD
Thiabendazole—Dyspepsia—Epirubicin—uterine cancer	0.000391	0.00199	CcSEcCtD
Thiabendazole—Decreased appetite—Epirubicin—uterine cancer	0.000387	0.00197	CcSEcCtD
Thiabendazole—Hypotension—Doxorubicin—uterine cancer	0.000384	0.00196	CcSEcCtD
Thiabendazole—Fatigue—Epirubicin—uterine cancer	0.000383	0.00195	CcSEcCtD
Thiabendazole—Feeling abnormal—Epirubicin—uterine cancer	0.000366	0.00187	CcSEcCtD
Thiabendazole—Somnolence—Doxorubicin—uterine cancer	0.000366	0.00186	CcSEcCtD
Thiabendazole—Gastrointestinal pain—Epirubicin—uterine cancer	0.000364	0.00185	CcSEcCtD
Thiabendazole—Dyspepsia—Doxorubicin—uterine cancer	0.000362	0.00184	CcSEcCtD
Thiabendazole—Decreased appetite—Doxorubicin—uterine cancer	0.000358	0.00182	CcSEcCtD
Thiabendazole—Fatigue—Doxorubicin—uterine cancer	0.000355	0.00181	CcSEcCtD
Thiabendazole—Abdominal pain—Epirubicin—uterine cancer	0.000351	0.00179	CcSEcCtD
Thiabendazole—Feeling abnormal—Doxorubicin—uterine cancer	0.000339	0.00173	CcSEcCtD
Thiabendazole—Gastrointestinal pain—Doxorubicin—uterine cancer	0.000336	0.00171	CcSEcCtD
Thiabendazole—Hypersensitivity—Epirubicin—uterine cancer	0.000328	0.00167	CcSEcCtD
Thiabendazole—Abdominal pain—Doxorubicin—uterine cancer	0.000325	0.00166	CcSEcCtD
Thiabendazole—Asthenia—Epirubicin—uterine cancer	0.000319	0.00162	CcSEcCtD
Thiabendazole—Pruritus—Epirubicin—uterine cancer	0.000315	0.0016	CcSEcCtD
Thiabendazole—Diarrhoea—Epirubicin—uterine cancer	0.000304	0.00155	CcSEcCtD
Thiabendazole—Hypersensitivity—Doxorubicin—uterine cancer	0.000303	0.00154	CcSEcCtD
Thiabendazole—Asthenia—Doxorubicin—uterine cancer	0.000295	0.0015	CcSEcCtD
Thiabendazole—Dizziness—Epirubicin—uterine cancer	0.000294	0.0015	CcSEcCtD
Thiabendazole—Pruritus—Doxorubicin—uterine cancer	0.000291	0.00148	CcSEcCtD
Thiabendazole—Vomiting—Epirubicin—uterine cancer	0.000283	0.00144	CcSEcCtD
Thiabendazole—Diarrhoea—Doxorubicin—uterine cancer	0.000281	0.00143	CcSEcCtD
Thiabendazole—Rash—Epirubicin—uterine cancer	0.00028	0.00143	CcSEcCtD
Thiabendazole—Dermatitis—Epirubicin—uterine cancer	0.00028	0.00143	CcSEcCtD
Thiabendazole—Headache—Epirubicin—uterine cancer	0.000279	0.00142	CcSEcCtD
Thiabendazole—Dizziness—Doxorubicin—uterine cancer	0.000272	0.00139	CcSEcCtD
Thiabendazole—Nausea—Epirubicin—uterine cancer	0.000264	0.00135	CcSEcCtD
Thiabendazole—Vomiting—Doxorubicin—uterine cancer	0.000262	0.00133	CcSEcCtD
Thiabendazole—Rash—Doxorubicin—uterine cancer	0.000259	0.00132	CcSEcCtD
Thiabendazole—Dermatitis—Doxorubicin—uterine cancer	0.000259	0.00132	CcSEcCtD
Thiabendazole—Headache—Doxorubicin—uterine cancer	0.000258	0.00131	CcSEcCtD
Thiabendazole—Nausea—Doxorubicin—uterine cancer	0.000244	0.00124	CcSEcCtD
